Treatment of acute myelogenous leukemia in the elderly.

abstract：:Recent data indicate that cellular immune responses can produce an anticancer effect. Two types of cellular immune responses appear to be clinically relevant: antigen specific immunity mediated by T cells that recognize tumor-associated peptide antigen expressed on surface HLA class I or class II molecules, and antige...

journal_title：Seminars in oncology

authors： Waller EK

更新日期：2004-04-01 00:00:00

abstract：:With the increasing numbers of breast cancers survivors, menopause, its symptoms, and its physical complications are becoming more prevalent problems in this patient population. Hormonal replacement, which has been the cornerstone therapy of menopausal related symptoms for decades, recently has been shown to increase ...

journal_title：Seminars in oncology

authors： Bruno D,Feeney KJ

更新日期：2006-12-01 00:00:00

abstract：:Significant achievements in the basic sciences have led to a greater knowledge of the underlying signaling pathways in renal cell cancer (RCC), including the mammalian target of rapamycin (mTOR) pathway (phosphoinositide 3-kinase/Akt pathway). The mTOR pathway has a central role in the regulation of cell growth and in...

journal_title：Seminars in oncology

authors： Pantuck AJ,Thomas G,Belldegrun AS,Figlin RA

更新日期：2006-10-01 00:00:00

abstract：:Robust pharmacodynamic assay results are valuable for informing go/no-go decisions about continued development of new anti-cancer agents and for identifying combinations of targeted agents, but often pharmacodynamic results are too incomplete or variable to fulfill this role. Our experience suggests that variable reag...

journal_title：Seminars in oncology

authors： Ferry-Galow KV,Makhlouf HR,Wilsker DF,Lawrence SM,Pfister TD,Marrero AM,Bigelow KM,Yutzy WH,Ji JJ,Butcher DO,Gouker BA,Kummar S,Chen AP,Kinders RJ,Parchment RE,Doroshow JH

更新日期：2016-08-01 00:00:00

abstract：:Knowledge of the pharmacokinetics of a drug is essential to the optimal design of the dose and schedule of chemotherapy protocols. As an extension, an understanding of the mechanism of drug action is necessary to construct the optimal strategy for combination chemotherapy. Nucleoside antimetabolites such as fludarabin...

journal_title：Seminars in oncology

authors： Plunkett W,Gandhi V,Huang P,Robertson LE,Yang LY,Gregoire V,Estey E,Keating MJ

更新日期：1993-10-01 00:00:00

abstract：:Alterations in chromatin structure resulting from aberrant DNA methylation and perturbations of the histone code profoundly influence gene expression during pulmonary carcinogenesis. Recent studies indicate that DNA demethylating agents and histone deacetylase (HDAC) inhibitors synergistically induce gene expression a...

journal_title：Seminars in oncology

authors： Schrump DS,Nguyen DM

更新日期：2005-10-01 00:00:00

abstract：:Fludara I.V. (fludarabine phosphate) (9-beta-D-arabinosyl-2-fluoroadenine, F-ara-A) is an adenine nucleoside analogue resistant to adenosine deaminase that shows promising therapeutic activity in the clinical treatment of lymphocytic hematologic malignancies. F-ara-A is transported into cells, where it is converted to...

journal_title：Seminars in oncology

authors： Plunkett W,Huang P,Gandhi V

更新日期：1990-10-01 00:00:00

abstract：:Quality of life (QOL) is an important consideration in the treatment of patients with advanced lung cancer because treatment is largely palliative. Moreover, QOL predicts survival in non-small cell lung cancer, and there is increasing acceptance by clinicians and regulatory authorities of symptoms and QOL as primary o...

journal_title：Seminars in oncology

authors： Cella D

更新日期：2004-12-01 00:00:00

abstract：:A primary goal of current clinical cancer research is the identification of prognostic tumor subtypes. It is increasingly clear that tumor growth depends on both internal tumor factors, and factors that are external to the tumor, such as microenvironment. We recently showed that parameter values alone are less importa...

journal_title：Seminars in oncology

authors： Pančoška P,Skála L,Nešetřil J,Carr BI

更新日期：2015-08-01 00:00:00

abstract：:Lymphoproliferative disorders are characterized by the abnormal accumulation of aberrant lymphocytes, which frequently interfere with the processes associated with immunologic response and hematopoiesis. Chronic lymphocytic leukemia (CLL) has traditionally been considered indolent, with a prolonged clinical course. Ho...

journal_title：Seminars in oncology

authors： Hillmen P

更新日期：2006-04-01 00:00:00

abstract：:Preclinical studies with zoledronic acid (Zometa; Novartis Pharmaceuticals Corp, East Hanover, NJ) have shown its potential in malignant bone disease. Clinical studies in the treatment of hypercalcemia of malignancy have been completed, as have phase I and II trials in patients with cancer and pre-existing bone metast...

journal_title：Seminars in oncology

authors： Coleman RE,Seaman JJ

更新日期：2001-04-01 00:00:00

abstract：:In this review, we briefly summarize some of the key developments in nutritional epidemiology and cancer over the past two decades with a focus on the strengths and limitations of study designs and dietary assessment methods. We present the evidence on dietary fat, meat, fiber, antioxidant nutrients, and calcium in re...

journal_title：Seminars in oncology

authors： Gibson TM,Ferrucci LM,Tangrea JA,Schatzkin A

更新日期：2010-06-01 00:00:00

abstract：:Organ function preservation in patients with head and neck cancer can be achieved by intensity-modulated radiation therapy (IMRT). Much of the work on the physics of IMRT has been done for currently available IMRT systems. However, clinical data remain scarce. Before IMRT is accepted as a standard of care, more compre...

journal_title：Seminars in oncology

authors： Chao KS,Ozyigit G,Thorsdad WL

更新日期：2003-12-01 00:00:00

abstract：:Cancer vaccines have shown success in curing tumors in preclinical models. Accumulating evidence also supports their ability to induce immune responses in patients. In many cases, these responses correlate with improved clinical outcomes. However, cancer vaccines have not yet demonstrated their true potential in clini...

journal_title：Seminars in oncology

authors： Keenan BP,Jaffee EM

更新日期：2012-06-01 00:00:00

abstract：:In order to correlate changes in morphology to changes in molecular attributes, we constructed a tissue microarray of thin and thick melanomas selected to represent progression from dysplasia to early and advanced melanoma. Hematoxylin and eosin (H&E) staining and immunohistology with antibodies to cyclin D1, p16, Ki6...

journal_title：Seminars in oncology

authors： Tuthill RJ,Reed RJ

更新日期：2007-12-01 00:00:00

abstract：:Lonidamine belongs to a new class of antineoplastics agents, since it does interfere with cell energy processes. When administered as single agent in metastatic breast cancer, it produces moderate therapeutic effects. The pattern of toxicity includes myalgias, asthenia, testicular pain, and gastrointestinal discomfort...

journal_title：Seminars in oncology

authors： Rosso R,Amoroso D,Gardin G,Miglietta L,Guido T,Pace M,Repetto L,Pronzato P

更新日期：1991-04-01 00:00:00

abstract：:This study reports the effectiveness and side effects of intravenous ondansetron as a single-agent antiemetic therapy for patients receiving emetogenic cancer chemotherapy under a compassionate-use program for patients not enrolled in controlled clinical trials. Patients were > or = 7 years old and had uncontrolled na...

journal_title：Seminars in oncology

authors： Berry WR,House KW,Lee JT,Plagge PB,Meshad MW,Grapski R

更新日期：1992-12-01 00:00:00

abstract：:Hematopoietic growth factors (HGFs) continue to be the most widely prescribed class of medications for patients with myelodysplastic syndromes (MDS), despite the advent of disease-modifying therapies for MDS (eg, azacitidine, decitabine, and lenalidomide) and the current absence of an MDS-specific US Food and Drug Adm...

journal_title：Seminars in oncology

authors： Steensma DP

更新日期：2011-10-01 00:00:00

abstract：:The outcomes in young adults aged 20-39 with sarcoma tend to be inferior compared to those in children and adolescents. There are differences in sarcoma histotype distribution with age, such that pediatric-type tumors predominate in the 20- to 25-year-old group while more adult-type sarcomas occur in those aged 35-39 ...

journal_title：Seminars in oncology

authors： Soliman H,Ferrari A,Thomas D

更新日期：2009-06-01 00:00:00

abstract：:In recent years, the most frequent indication for high-dose autologous stem-cell-supported chemotherapy in the United States has been breast cancer. This approach is applied in "high-risk," early-stage disease as adjuvant treatment, and with either curative or palliative intent in metastatic disease. Among both lay pe...

journal_title：Seminars in oncology

authors： Hudis CA,Münster PN

更新日期：1999-02-01 00:00:00

abstract：:One of the most known oncogenes is the epidermal growth factor receptor (EGFR) family. It activates multiple signaling cascades that promote carcinogenesis and immune evasion. Therefore, these molecules have been extensively targeted in cancer immunotherapy. Beyond EGFR signaling cascade inhibition, some of these agen...

journal_title：Seminars in oncology

authors： Mazorra Z,Chao L,Lavastida A,Sanchez B,Ramos M,Iznaga N,Crombet T

更新日期：2018-01-01 00:00:00

abstract：:Solid organ tumors associated with neoangiogenesis, as measured by increased microvessel density (MVD), have poorer prognoses. A similar observation of increased MVD has been made in hematologic malignancies; however, its prognostic significance remains unknown. We investigated changes in MVD in 122 newly diagnosed mu...

journal_title：Seminars in oncology

authors： Munshi NC,Wilson C

更新日期：2001-12-01 00:00:00

abstract：:Hepatocellular carcinoma (HCC), one of the most common cancers worldwide, usually develops in a liver already suffering from chronic damages, often cirrhosis. There has been marked progress in the treatment of HCC. However, effective treatments are limited to patients with less advanced HCC. The detection of HCC at an...

journal_title：Seminars in oncology

authors： Masuzaki R,Karp SJ,Omata M

更新日期：2012-08-01 00:00:00

abstract：:From this brief review is should be evident that the hereditary varieties of common cancers are characterized by a high degree of genetic heterogeneity. The specific types of hereditary cancers can be identified by focusing on the histologic types and sites of involvement, not only of the primary neoplasm, but also of...

journal_title：Seminars in oncology

authors： Anderson DE

更新日期：1978-03-01 00:00:00

abstract：:Cancer cells that express excessive levels of Bcl-2 pose a major problem in the delivery of curative therapy. Most treatments for such cancer involve chemotherapy to induce the apoptotic process. While these therapies often result in disease control for periods of time, failure to initiate apoptosis as a result of acq...

journal_title：Seminars in oncology

authors： Cotter FE

更新日期：2004-12-01 00:00:00

abstract：:Surgery is the major curative treatment modality for patients with malignant disease. However, surgery also plays an important role in supportive and palliative care of cancer patients. In settings in which maintaining quality of life rather than prolongation of survival is the major goal of treatment, the potential m...

journal_title：Seminars in oncology

authors： Markman M

更新日期：1995-04-01 00:00:00

abstract：:Etoposide is one of the few cancer chemotherapy agents that is schedule-dependent in both preclinical and clinical studies. A randomized trial of etoposide as initial therapy in extensive small cell lung cancer (SCLC) demonstrated the superiority of a 5-day course versus the same total dose administered over 24 hours....

journal_title：Seminars in oncology

authors： Einhorn LH

更新日期：1991-02-01 00:00:00

abstract：:Eighteen percent of incident malignancies in the United States are a second (or subsequent) cancer. Second primary neoplasms (SPNs), particularly solid tumors, are a major cause of mortality and serious morbidity among cancer survivors successfully cured of their first cancer. Multiple etiologies may lead to a cancer ...

journal_title：Seminars in oncology

authors： Oeffinger KC,Baxi SS,Novetsky Friedman D,Moskowitz CS

更新日期：2013-12-01 00:00:00

abstract：:A large body of work spanning the past decade has identified the molecular chaperone heat shock protein 90 (Hsp90) as a critical modulator of an extensive network of cellular signaling pathways. Many of the processes overseen by Hsp90 are deregulated in tumor cells, including cell cycle control, gene transcription, an...

journal_title：Seminars in oncology

authors： Cullinan SB,Whitesell L

更新日期：2006-08-01 00:00:00

abstract：:The majority of patients with advanced prostatic cancer respond either to castration or estrogen therapy. In an attempt to identify an alternative hormonal therapy, 25 symptomatic stage D prostate cancer patients were treated with megestrol acetate as initial hormonal therapy. Thirty-three patients were evaluable for ...

journal_title：Seminars in oncology

authors： Bonomi P,Pessis D,Bunting N,Block M,Anderson K,Wolter J,Rossof A,Slayton R,Harris J

更新日期：1985-03-01 00:00:00